Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 20/20 | 1.00 |
| ▸ | INSR | P06213 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | LTK | P29376 | 2/20 | 1.00 |
| ▸ | AXL | P30530 | 2/20 | 1.00 |
| ▸ | IRAK1 | P51617 | 2/20 | 1.00 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 1.00 |
| ▸ | MERTK | Q12866 | 2/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21206279 | 1.00 | ALK (1.00) | ALKINSRLCKLTKAXL | |
| SCHEMBL19328244 | 1.00 | ALK (1.00) | ALKINSRLCKLTKAXL | |
| SCHEMBL19328243 | 1.00 | ALK (1.00) | ALKINSRLCKLTKAXL | |
| SCHEMBL23810096 | 0.95 | ALK (0.90) | ALKINSRLCKLTKAXL | |
| SCHEMBL23810121 | 0.95 | ALK (0.90) | ALKINSRLCKLTKAXL | |
| SCHEMBL23915691 | 0.91 | ALK (0.88) | ALKINSRLCKLTKAXL | |
| SCHEMBL21135589 | 0.91 | ALK (0.88) | ALKINSRLCKLTKAXL | |
| SCHEMBL21759921 | 0.91 | ALK (1.00) | ALKINSRLCKLTKAXL | |
| SCHEMBL24046489 | 0.91 | ALK (1.00) | ALKINSRLCKLTKAXL | |
| SCHEMBL573767 | 0.89 | ALK (0.82) | ALKINSRLCKLTKAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 645 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735002-A1 | TREATMENT METHODS FOR SUBJECTS WITH NON-SMALL CELL LUNG CANCER HAVING AN ABERRATION IN EGFR | Taiho Pharmaceutical Co., Ltd. (JP) | 2026-05-06 | — | — | EP | claimed |
| EP-4221706-B1 | TREATMENT FOR VIRAL INFECTION | UNIV OSLO HF (NO) | 2026-04-15 | — | — | EP | claimed |
| WO-2025238172-A1 | COMBINATIONS OF BRAF AND ALK/TRK INHIBITORS FOR COLORECTAL CANCER | GENOME RESEARCH LIMITED (GB) | 2025-11-20 | — | — | WO | claimed |
| EP-4637832-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | Tubulis GmbH (DE) | 2025-10-29 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2025128880-A1 | CD70 TARGETING IN CANCER WITH ACQUIRED RESISTANCE TO TARGETED THERAPEUTIC AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-06-19 | — | — | WO | claimed |
| US-20250146076-A1 | ALK GENE FUSIONS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-05-08 | — | — | US | claimed |
| US-20250129429-A1 | GENE FUSIONS IN SARCOMA | FOUNDATION MEDICINE, INC. (US) | 2025-04-24 | — | — | US | claimed |
| US-20250057963-A1 | DISCOVERY OF PIPERLONGUMINE AS A NOVEL E3 LIGASE LIGAND | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-02-20 | — | — | US | claimed |
| WO-2025006697-A1 | TREATMENT METHODS FOR SUBJECTS WITH NON-SMALL CELL LUNG CANCER HAVING AN ABERRATION IN EGFR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-01-02 | — | — | WO | claimed |
| EP-4054579-A1 | METHODS FOR THE TREATMENT OF CANCERS THAT HAVE ACQUIRED RESISTANCE TO KINASE INHIBITORS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-09-14 | — | — | EP | claimed |
| WO-2022165214-A1 | METHODS OF TREATING CANCER WITH KINASE INHIBITORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-08-04 | — | — | WO | claimed |
| US-20220243280-A1 | NTRK FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-08-04 | — | — | US | claimed |
| CN-114761006-A | Methods of treating cancer resistant to kinase inhibitors | INSERM(法国国家健康医学研究院) | 2022-07-15 | — | — | CN | claimed |
| WO-2022147163-A1 | ALK FUSION GENES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-07-07 | — | — | WO | claimed |
| US-20220143049-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | VALERIO THERAPEUTICS (FR) | 2022-05-12 | — | — | US | claimed |
| CN-114364798-A | Combination of Dbait molecules with kinase inhibitors for the treatment of cancer | 欧恩科斯欧公司 | 2022-04-15 | — | — | CN | claimed |
| EP-3980563-A2 | NTRK FUSION MOLECULES AND USES THEREOF | Foundation Medicine, Inc. (US) | 2022-04-13 | — | — | EP | claimed |
| WO-2022069684-A1 | TREATMENT FOR VIRAL INFECTION | OSLO UNIVERSITETSSYKEHUS HF (NO) | 2022-04-07 | — | — | WO | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220243280-A1 | NTRK FUSION MOLECULES AND USES THEREOF | NTRK1, NTRK3, NTRK2 | ALK 6/4885INSR 2754/4885LCK 332/4885 |
| US-20220143049-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | MAP3K20, MAP3K10, DCK | ALK 566/4885INSR 2378/4885LCK 91/4885 |
| US-20250057963-A1 | DISCOVERY OF PIPERLONGUMINE AS A NOVEL E3 LIGASE LIGAND | CDK10, CDK20, CDK9 | ALK 619/4885INSR 3500/4885LCK 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.